1. Ma, Xiaoshi, Chen, Lipeng, Chen, Tao, Xiao, Kefeng, Guo, Jinan. 2023. Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer. In Computational and structural biotechnology journal, 21, 5476-5490. doi:10.1016/j.csbj.2023.10.044. https://pubmed.ncbi.nlm.nih.gov/38022698/
2. Soejima, Yurie, Takeuchi, Miho, Miyamoto, Nao, Sawabe, Motoji, Fukusato, Toshio. 2021. ITGB6-Knockout Suppresses Cholangiocarcinoma Cell Migration and Invasion with Declining PODXL2 Expression. In International journal of molecular sciences, 22, . doi:10.3390/ijms22126303. https://pubmed.ncbi.nlm.nih.gov/34208313/
3. Mao, Guocai, Li, Jing, Wang, Nan, Jiang, Junhong, Ma, Haitao. 2024. SIRPG promotes lung squamous cell carcinoma pathogenesis via M1 macrophages: a multi-omics study integrating data and Mendelian randomization. In Frontiers in oncology, 14, 1392417. doi:10.3389/fonc.2024.1392417. https://pubmed.ncbi.nlm.nih.gov/38894865/
4. Wang, Li, Yu, Lei, Shi, Jian, Ning, Shangwei, Zhao, Hongying. 2022. Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer. In Scientific reports, 12, 10641. doi:10.1038/s41598-022-13835-5. https://pubmed.ncbi.nlm.nih.gov/35739271/
5. Zengin, Talip, Önal-Süzek, Tuğba. 2020. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma. In BMC bioinformatics, 21, 368. doi:10.1186/s12859-020-03691-3. https://pubmed.ncbi.nlm.nih.gov/32998690/
智鼠故事 
